Sandra Radzicka-Mularczyk
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sandra Radzicka-Mularczyk has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Marek Pietryga
Poznan Univ Med Sci, Dept Gynecol Obstet & Gynecol Oncol, Div Obstet & Womens Dis, Polna St 33, PL-60535 Poznan, Poland
3 shared publicationsJacek Brazert
Department of Gynecology, Obstetrics and Gynecologic Oncology, Division of Obstetrics and Women’s Diseases, Poznan University of Medical Sciences, Poland
2 shared publicationsJacek Brązert
Poznan Univ Med Sci, Dept Gynecol Obstet & Gynecol Oncol, Div Obstet & Womens Dis, Polna St 33, PL-60535 Poznan, Poland
2 shared publications- Aleksandra Gladych-Macioszek
Department of Reproduction, Chair of Fetomaternal Medicine, Poznan University of Medical Sciences, Poznan, Poland
1 shared publication - Ewa Wender-Ozegowska
Department of Reproduction, Chair of Fetomaternal Medicine, Poznan University of Medical Sciences, Poznan, Poland
1 shared publication - Gernot Desoye
Department of Obstetrics and Gynaecology, Medical University of Graz, Auenbruggerplatz 14, 8036 Graz, Austria
1 shared publication
Latest Publications
- Open Access
- 11 March 2026
- Published by Springer Nature in BMC Pregnancy and Childbirth
- Vol. 26 (1)
Early gestational diabetes mellitus and type 2 diabetes: do they differ in perinatal outcome– a retrospective analysis
The rise in type 2 diabetes (T2D) during pregnancy is mainly due to increasing obesity and metabolic disorders. Early gestational diabetes mellitus (eGDM),
- 11 March 2026
- Published by Springer Nature in BMC Pregnancy and Childbirth
- Vol. 26 (1)
Open AccessEarly gestational diabetes mellitus and type 2 diabetes: do they differ in perinatal outcome– a retrospective analysis
The rise in type 2 diabetes (T2D) during pregnancy is mainly due to increasing obesity and metabolic disorders. Early gestational diabetes mellitus (eGDM),
- 1 January 2022
- Published by Edizioni Minerva Medica in Minerva Endocrinology
- Vol. 46 (4) , 396-405
Serum visfatin as a metabolic biomarker in obese patients with gestational diabetes mellitus
Article: Serum visfatin as a metabolic biomarker in obese patients with gestational diabetes mellitus - Minerva Endocrinology 2021 December;46(4):396-405 - Minerva Medica - Journals
- 1 January 2022
- Published by Edizioni Minerva Medica in Minerva Endocrinology
- Vol. 46 (4) , 396-405
Serum visfatin as a metabolic biomarker in obese patients with gestational diabetes mellitus
Article: Serum visfatin as a metabolic biomarker in obese patients with gestational diabetes mellitus - Minerva Endocrinology 2021 December;46(4):396-405 - Minerva Medica - Journals
- 31 December 2020
- Published by VM Media Group sp. z o.o in Ginekologia Polska
- Vol. 91 (12) , 769-772
How mother’s obesity may affect the pregnancy and offspring
One of the main reasons for the epidemic of obesity, which has already influenced the economic condition of health system worldwide, is our modern lifestyle having an unbalanced calorie intake and insufficient physical activity. Maternal-fetal nourishment and metabolism are the mechanisms of fetal programming of obesity-adiposity and non-communicable diseases that have been most extensively investigated. A mother’s obesity is related to adverse outcomes for both mother and baby. Maternal overnutrition is also associated with a higher risk of gestational diabetes, preterm birth, large-for-gestational-age babies, fetal defects, congenital anomalies, and perinatal death. Women with obesity should be encouraged to reduce their body mass index (BMI) prior to pregnancy, and to limit weight gain during pregnancy. Obstetric ultrasound imaging in pregnant women is negatively affected by abdominal adipose tissue, having an adverse influence on congenital anomaly detection rates and the estimation of fetal weight. One of the main reasons for the epidemic of obesity, which has already influenced the economic condition of health system worldwide, is our modern lifestyle having an unbalanced calorie intake and insufficient physical activity. Maternal-fetal nourishment and metabolism are the mechanisms of fetal programming of obesity-adiposity and non-communicable diseases that have been most extensively investigated. A mother’s obesity is related to adverse outcomes for both mother and baby. Maternal overnutrition is also associated with a higher risk of gestational diabetes, preterm birth, large-for-gestational-age babies, fetal defects, congenital anomalies, and perinatal death. Women with obesity should be encouraged to reduce their body mass index (BMI) prior to pregnancy, and to limit weight gain during pregnancy. Obstetric ultrasound imaging in pregnant women is negatively affected by abdominal adipose tissue, having an adverse influence on congenital anomaly detection rates and the estimation of fetal weight.
- 31 December 2020
- Published by VM Media Group sp. z o.o in Ginekologia Polska
- Vol. 91 (12) , 769-772
How mother’s obesity may affect the pregnancy and offspring
One of the main reasons for the epidemic of obesity, which has already influenced the economic condition of health system worldwide, is our modern lifestyle having an unbalanced calorie intake and insufficient physical activity. Maternal-fetal nourishment and metabolism are the mechanisms of fetal programming of obesity-adiposity and non-communicable diseases that have been most extensively investigated. A mother’s obesity is related to adverse outcomes for both mother and baby. Maternal overnutrition is also associated with a higher risk of gestational diabetes, preterm birth, large-for-gestational-age babies, fetal defects, congenital anomalies, and perinatal death. Women with obesity should be encouraged to reduce their body mass index (BMI) prior to pregnancy, and to limit weight gain during pregnancy. Obstetric ultrasound imaging in pregnant women is negatively affected by abdominal adipose tissue, having an adverse influence on congenital anomaly detection rates and the estimation of fetal weight. One of the main reasons for the epidemic of obesity, which has already influenced the economic condition of health system worldwide, is our modern lifestyle having an unbalanced calorie intake and insufficient physical activity. Maternal-fetal nourishment and metabolism are the mechanisms of fetal programming of obesity-adiposity and non-communicable diseases that have been most extensively investigated. A mother’s obesity is related to adverse outcomes for both mother and baby. Maternal overnutrition is also associated with a higher risk of gestational diabetes, preterm birth, large-for-gestational-age babies, fetal defects, congenital anomalies, and perinatal death. Women with obesity should be encouraged to reduce their body mass index (BMI) prior to pregnancy, and to limit weight gain during pregnancy. Obstetric ultrasound imaging in pregnant women is negatively affected by abdominal adipose tissue, having an adverse influence on congenital anomaly detection rates and the estimation of fetal weight.
- Open Access
- 26 July 2019
- Published by VM Media Group sp. z o.o in Ginekologia Polska
- Vol. 90 (7) , 381-387
Serum homocysteine and vitamin B12 levels in women with gestational diabetes mellitus
Gestational diabetes mellitus (GDM) is described as a glucose intolerance of variable severity which begun or was firstly recognized during gravidity. Two major metabolic disorders, insulin resistance and β-cell dysfunction, currently play major role in pathogenesis of GDM. Our intention was to investigate total serum homocysteine and vitamin B12 levels in pregnant women with GDM and non-diabetic gravid women. Serum homocysteine and vitamin B12 levels were prospectively measured in a total of 79 pregnant women, 60 of whom were diagnosed with GDM, and 19 of whom were healthy controls. Serum homocysteine levels were analyzed by ELISA. Vitamin B12 concentrations were determined by chemiluminescent immunoassay, and lipids were determined enzymatically. GDM and control groups did not differ in terms of the serum homocysteine levels (median 7.24 vs 7.97 umol/L, respectively, p = 0.15). Nor did we find any association between serum homocysteine levels and BMI (r = 0.06, p = 0.55, respectively). There was no correlation between serum homocysteine and fasting serum glucose (r = 0.3, p = 0.8, respectively). There was no relationship between serum homocysteine concentrations and glycosylated hemoglobin (HgbA1c) levels (r = 0.06, p = 0.67, respectively). Serum vitamin B12 concentrations did not differ between the GDM and control groups (median 286 vs 262 pg/mL, respectively, p = 0.17). We found that levels of Vitamin B12 correlated inversely with fasting serum glucose concentrations (r = -0.44, p = 0.0009). Vitamin B12 concentrations increased along with LDL (r = 0.27, p = 0.043) and HDL (r = 0.38, p = 0.004) levels, however were inversely correlated with serum triglycerides (r = -0.34, p = 0.009). GDM patients with low Vitamin B12 values tend to have higher fasting serum glucose and altered lipid profiles (high triglycerides, low HDL and LDL). In women with GDM, serum homocysteine levels are not associated with HbA1c level, fasting glycemia, or BMI.
- 26 July 2019
- Published by VM Media Group sp. z o.o in Ginekologia Polska
- Vol. 90 (7) , 381-387
Open AccessSerum homocysteine and vitamin B12 levels in women with gestational diabetes mellitus
Gestational diabetes mellitus (GDM) is described as a glucose intolerance of variable severity which begun or was firstly recognized during gravidity. Two major metabolic disorders, insulin resistance and β-cell dysfunction, currently play major role in pathogenesis of GDM. Our intention was to investigate total serum homocysteine and vitamin B12 levels in pregnant women with GDM and non-diabetic gravid women. Serum homocysteine and vitamin B12 levels were prospectively measured in a total of 79 pregnant women, 60 of whom were diagnosed with GDM, and 19 of whom were healthy controls. Serum homocysteine levels were analyzed by ELISA. Vitamin B12 concentrations were determined by chemiluminescent immunoassay, and lipids were determined enzymatically. GDM and control groups did not differ in terms of the serum homocysteine levels (median 7.24 vs 7.97 umol/L, respectively, p = 0.15). Nor did we find any association between serum homocysteine levels and BMI (r = 0.06, p = 0.55, respectively). There was no correlation between serum homocysteine and fasting serum glucose (r = 0.3, p = 0.8, respectively). There was no relationship between serum homocysteine concentrations and glycosylated hemoglobin (HgbA1c) levels (r = 0.06, p = 0.67, respectively). Serum vitamin B12 concentrations did not differ between the GDM and control groups (median 286 vs 262 pg/mL, respectively, p = 0.17). We found that levels of Vitamin B12 correlated inversely with fasting serum glucose concentrations (r = -0.44, p = 0.0009). Vitamin B12 concentrations increased along with LDL (r = 0.27, p = 0.043) and HDL (r = 0.38, p = 0.004) levels, however were inversely correlated with serum triglycerides (r = -0.34, p = 0.009). GDM patients with low Vitamin B12 values tend to have higher fasting serum glucose and altered lipid profiles (high triglycerides, low HDL and LDL). In women with GDM, serum homocysteine levels are not associated with HbA1c level, fasting glycemia, or BMI.
- Open Access
- 28 September 2018
- Published by VM Media Group sp. z o.o in Ginekologia Polska
- Vol. 89 (9) , 518-521
The role of visfatin in pathogenesis of gestational diabetes (GDM)
Gestational diabetes (GDM) is defined as a glucose intolerance of varying severity with onset or first recognition during pregnancy. Two major metabolic disorders: insulin resistance and β-cells dysfunction, play currently major role in pathogenesis of GDM. Adipose tissue is an organ involved in production of adipokines, which have various influence on metabolism of glucose and lipids. Visfatin is an adipokine mainly produced and secreted by the fat tissue. It exerts an insulin-like effect by binding to the insulin receptor-1 and have hypoglycemic effect. Visfatin appears to be an important factor in the pathophysiology of GDM. The aim of this article is to review the literature concerning the relationship between the adipokine mentioned above and GDM, and to clarify its role in the pathophysiology of GDM. Gestational diabetes (GDM) is defined as a glucose intolerance of varying severity with onset or first recognition during pregnancy. Two major metabolic disorders: insulin resistance and β-cells dysfunction, play currently major role in pathogenesis of GDM. Adipose tissue is an organ involved in production of adipokines, which have various influence on metabolism of glucose and lipids. Visfatin is an adipokine mainly produced and secreted by the fat tissue. It exerts an insulin-like effect by binding to the insulin receptor-1 and have hypoglycemic effect. Visfatin appears to be an important factor in the pathophysiology of GDM. The aim of this article is to review the literature concerning the relationship between the adipokine mentioned above and GDM, and to clarify its role in the pathophysiology of GDM.
- 28 September 2018
- Published by VM Media Group sp. z o.o in Ginekologia Polska
- Vol. 89 (9) , 518-521
Open AccessThe role of visfatin in pathogenesis of gestational diabetes (GDM)
Gestational diabetes (GDM) is defined as a glucose intolerance of varying severity with onset or first recognition during pregnancy. Two major metabolic disorders: insulin resistance and β-cells dysfunction, play currently major role in pathogenesis of GDM. Adipose tissue is an organ involved in production of adipokines, which have various influence on metabolism of glucose and lipids. Visfatin is an adipokine mainly produced and secreted by the fat tissue. It exerts an insulin-like effect by binding to the insulin receptor-1 and have hypoglycemic effect. Visfatin appears to be an important factor in the pathophysiology of GDM. The aim of this article is to review the literature concerning the relationship between the adipokine mentioned above and GDM, and to clarify its role in the pathophysiology of GDM. Gestational diabetes (GDM) is defined as a glucose intolerance of varying severity with onset or first recognition during pregnancy. Two major metabolic disorders: insulin resistance and β-cells dysfunction, play currently major role in pathogenesis of GDM. Adipose tissue is an organ involved in production of adipokines, which have various influence on metabolism of glucose and lipids. Visfatin is an adipokine mainly produced and secreted by the fat tissue. It exerts an insulin-like effect by binding to the insulin receptor-1 and have hypoglycemic effect. Visfatin appears to be an important factor in the pathophysiology of GDM. The aim of this article is to review the literature concerning the relationship between the adipokine mentioned above and GDM, and to clarify its role in the pathophysiology of GDM.